Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA015462)
Article History
Received: 15 September 2023
Accepted: 31 January 2024
First Online: 8 February 2024
Declarations
:
: MKG is a consultant for Indivior Inc., which makes buprenorphine products; however, Indivior played no role in this study. The authors declare no conflict of interest with respect to the conduct or content of this work.
: The contents of the paper are solely the responsibility of the authors.